156 related articles for article (PubMed ID: 36712831)
21. Understanding the Socioeconomic and Geographical Characteristics of Beneficiaries Receiving a Comprehensive Medication Review.
Chou J; Pellegrin K; Cooke CE; Zarowitz B; Hanlon A; Lozano A; Brandt NJ
J Manag Care Spec Pharm; 2020 Oct; 26(10):1276-1281. PubMed ID: 32996388
[TBL] [Abstract][Full Text] [Related]
22. Racial and ethnic disparities in the enrolment of medicare medication therapy management programs.
Garuccio J; Tsang CCS; Wan JY; Shih YCT; Chisholm-Burns MA; Dagogo-Jack S; Cushman WC; Dong X; Browning JA; Zeng R; Wang J
J Pharm Health Serv Res; 2023 Jun; 14(2):188-197. PubMed ID: 37337596
[TBL] [Abstract][Full Text] [Related]
23. Potential effects of racial and ethnic disparities in meeting Medicare medication therapy management eligibility criteria.
Wang J; Qiao Y; Tina Shih YC; Spivey CA; Dagogo-Jack S; Wan JY; White-Means SI; Cushman WC; Chisholm-Burns MA
J Pharm Health Serv Res; 2014 Jun; 5(2):109-118. PubMed ID: 25045406
[TBL] [Abstract][Full Text] [Related]
24. Historical trend of disparity implications of Medicare MTM eligibility criteria.
Wang J; Qiao Y
Res Social Adm Pharm; 2013; 9(6):758-69. PubMed ID: 23062785
[TBL] [Abstract][Full Text] [Related]
25. Historical trend of racial and ethnic disparities in meeting Medicare medication therapy management eligibility in non-Medicare population.
Wang J; Surbhi S; Zhang Z; Spivey CA; Chisholm-Burns M
Res Social Adm Pharm; 2014; 10(6):904-917. PubMed ID: 25458405
[TBL] [Abstract][Full Text] [Related]
26. Disparity Implications of Proposed 2015 Medicare Eligibility Criteria for Medication Therapy Management Services.
Wang J; Qiao Y; Spivey CA; Li C; Clark C; Deng Y; Liu F; Tillman J; Chisholm-Burns M
J Pharm Health Serv Res; 2016 Dec; 7(4):209-215. PubMed ID: 28025599
[TBL] [Abstract][Full Text] [Related]
27. Racial and ethnic disparities associated with the measure for drug-drug interactions among Medicare beneficiaries.
Browning J; Tsang CCS; Wan JY; Chisholm-Burns MA; Dagogo-Jack S; Cushman WC; Dong X; Wang J
J Am Pharm Assoc (2003); 2022; 62(1):142-149. PubMed ID: 34509379
[TBL] [Abstract][Full Text] [Related]
28. Higher Predictive Value Positive for MMA Than ACA MTM Eligibility Criteria Among Racial and Ethnic Minorities: An Observational Study.
Qiao Y; Spivey CA; Wang J; Shih YT; Wan JY; Kuhle J; Dagogo-Jack S; Cushman WC; Chisholm-Burns MA
Inquiry; 2018; 55():46958018795749. PubMed ID: 30175638
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive Medication Review Completion Rates and Disparities After Medicare Star Rating Measure.
Hung A; Wilson L; Smith VA; Pavon JM; Sloan CE; Hastings SN; Farley J; Maciejewski ML
JAMA Health Forum; 2024 May; 5(5):e240807. PubMed ID: 38700854
[TBL] [Abstract][Full Text] [Related]
30. Addressing racial/ethnic disparities associated with Medicare Part D Star Ratings among population with Alzheimer's disease and related dementias.
Tsang CCS; Wang J
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(9):1067-1075. PubMed ID: 37551695
[TBL] [Abstract][Full Text] [Related]
31. Positive Medication Changes Resulting from Comprehensive and Noncomprehensive Medication Reviews in a Medicare Part D Population.
Buhl A; Augustine J; Taylor AM; Martin R; Warholak TL
J Manag Care Spec Pharm; 2017 Mar; 23(3):388-394. PubMed ID: 28230451
[TBL] [Abstract][Full Text] [Related]
32. Medicare Medication Therapy Management: beneficiary characteristics and utilization patterns in a national CMS Medicare fee-for-service sample (2013-2016).
Oyarzún-González X; Abner EL; Freeman P; Kucharska-Newton A; Fardo DW; Moga DC
J Am Pharm Assoc (2003); 2024 May; ():102140. PubMed ID: 38825153
[TBL] [Abstract][Full Text] [Related]
33. Solving racial/ethnic disparities associated with Medicare Part D Star Ratings.
Dong X; Tsang CCS; Browning JA; Sim Y; Wan JY; Chisholm-Burns MA; Dagogo-Jack S; Cushman WC; Wang J
Curr Med Res Opin; 2023 Jul; 39(7):963-971. PubMed ID: 37219396
[TBL] [Abstract][Full Text] [Related]
34. Evolution of the Medicare Part D Medication Therapy Management Program from Inception in 2006 to the Present.
Gray C; Cooke CE; Brandt N
Am Health Drug Benefits; 2019 Sep; 12(5):243-251. PubMed ID: 32015791
[TBL] [Abstract][Full Text] [Related]
35. Disparities associated with Medicare Part D Star Ratings measures among patients with Alzheimer's disease and related dementias.
Tsang CCS; Zhang X; Barenie RE; Cernasev A; Miller NA; Wan JY; Tsao JW; Wang J
Medicine (Baltimore); 2023 May; 102(18):e33641. PubMed ID: 37144996
[TBL] [Abstract][Full Text] [Related]
36. Analysis of pharmacist-provided medication therapy management (MTM) services in community pharmacies over 7 years.
Barnett MJ; Frank J; Wehring H; Newland B; VonMuenster S; Kumbera P; Halterman T; Perry PJ
J Manag Care Pharm; 2009; 15(1):18-31. PubMed ID: 19125547
[TBL] [Abstract][Full Text] [Related]
37. Nationwide estimates of medication therapy management delivery under the Medicare prescription drug benefit.
Pestka DL; Zillich AJ; Coe AB; Farris KB; Adeoye OA; Snyder ME; Farley JF
J Am Pharm Assoc (2003); 2020; 60(3):456-461. PubMed ID: 31926872
[TBL] [Abstract][Full Text] [Related]
38. Factors affecting demand among older adults for medication therapy management services.
Brooks JM; Unni EJ; Klepser DG; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2008 Dec; 4(4):309-19. PubMed ID: 19064238
[TBL] [Abstract][Full Text] [Related]
39. Disparity implications of Medicare eligibility criteria for medication therapy management services.
Wang J; Mullins CD; Brown LM; Shih YC; Dagogo-Jack S; Hong SH; Cushman WC
Health Serv Res; 2010 Aug; 45(4):1061-82. PubMed ID: 20500223
[TBL] [Abstract][Full Text] [Related]
40. Assessment of the impact of medication therapy management delivered to home-based Medicare beneficiaries.
Welch EK; Delate T; Chester EA; Stubbings T
Ann Pharmacother; 2009 Apr; 43(4):603-10. PubMed ID: 19318600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
